Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities.
An open clinical trial was performed to determine whether or not the antithrombotic drug cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-qui nolinone, OPC-13013) at 150 mg/day would increase ankle blood flow in 13 lower extremities in 9 patients with chronic arterial occlusion. After 2 weeks of treatment, ankle blood flow in the lower extremities increased by a mean of 16.16 +/- 7.08% (p less than 0.05, t-test) over the initial level. From these results, it was concluded that cilostazol has a significant beneficial hemodynamic effect on chronic arterial occlusion in the extremities.
D000368:Aged; D000842:Ankle / Q000098:blood supply; D001157:Arterial Occlusive Diseases / Q000188:drug therapy / Q000503:physiopathology*; D001393:Azoles / Q000494:pharmacology*; D002908:Chronic Disease; D000077407:Cilostazol; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012039:Regional Blood Flow / Q000187:drug effects; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use
D001393:Azoles; D005343:Fibrinolytic Agents; D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol